5 results
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
#SideEffects #Table ... #DecisionAid #Orals ... #DM2 #Diabetes ... #Endocrinology # ... Pharmacology #Management
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
Rybelsus (oral semaglutide ... -1 Agonist Dosing ... drug to remain stable ... #Diabetes #Pharmacology ... #Endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... Ozempic), or daily tablet ... (Rybelsus) Major ... #Summary #DM2 # ... diabetes #endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
to treat Type 2 Diabetes ... There is an ORAL ... GLP1 #Agonists #Pharmacology ... #Dosing #Diabetes ... #DM2 #Endocrinology
Insulin Calculations for Type 1 Diabetes 

Insulin-to-Carb Ratio (ICR) 500/TDD = #g of carbs covered by
Insulin Calculations ... for Type 1 Diabetes ... used in dosing ... #DM1 #Pharmacology ... #Endocrinology